Association of p16 expression with prognosis varies across ovarian carcinoma histotypes
Standard
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes : an Ovarian Tumor Tissue Analysis consortium study. / Rambau, Peter F; Vierkant, Robert A; Intermaggio, Maria P; Kelemen, Linda E; Goodman, Marc T; Herpel, Esther; Pharoah, Paul D; Kommoss, Stefan; Jimenez-Linan, Mercedes; Karlan, Beth Y; Gentry-Maharaj, Aleksandra; Menon, Usha; Polo, Susanna Hernando; Candido Dos Reis, Francisco J; Doherty, Jennifer Anne; Gayther, Simon A; Sharma, Raghwa; Larson, Melissa C; Harnett, Paul R; Hatfield, Emma; de Andrade, Jurandyr M; Nelson, Gregg S; Steed, Helen; Schildkraut, Joellen M; Carney, Micheal E; Høgdall, Estrid; Whittemore, Alice S; Widschwendter, Martin; Kennedy, Catherine J; Wang, Frances; Wang, Qin; Wang, Chen; Armasu, Sebastian M; Daley, Frances; Coulson, Penny; Jones, Micheal E; Anglesio, Micheal S; Chow, Christine; de Fazio, Anna; García-Closas, Montserrat; Brucker, Sara Y; Cybulski, Cezary; Harris, Holly R; Hartkopf, Andreas D; Huzarski, Tomasz; Jensen, Allan; Lubiński, Jan; Oszurek, Oleg; Benitez, Javier; Mina, Fady; Staebler, Annette; Taran, Florin Andrei; Pasternak, Jana; Talhouk, Aline; Rossing, Mary Anne; Hendley, Joy; Edwards, Robert P; Fereday, Sian; Modugno, Francesmary; Ness, Roberta B; Sieh, Weiva; El-Bahrawy, Mona A; Winham, Stacey J; Lester, Jenny; Kjaer, Susanne K; Gronwald, Jacek; Sinn, Peter; Fasching, Peter A; Chang-Claude, Jenny; Moysich, Kirsten B; Bowtell, David D; Hernandez, Brenda Y; Luk, Hugh; Behrens, Sabine; Shah, Mitul; Ghatage, Prafull; Alsop, Jennifer; Alsop, Kathryn; García-Donas, Jesús; Thompson, Pamela J; Swerdlow, Anthony J; Karpinskyj, Chloe; Cazorla-Jiménez, Alicia; García, María J; Deen, Susha; Wilkens, Lynne R; Palacios, José; Berchuck, Andrew; Koziak, Jennifer M; Brenton, James D; Cook, Linda S; Goode, Ellen L; Huntsman, David G; Ramus, Susan J; Köbel, Martin; AOCS study group.
in: J PATHOL CLIN RES, Jahrgang 4, Nr. 4, 10.2018, S. 250-261.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Association of p16 expression with prognosis varies across ovarian carcinoma histotypes
T2 - an Ovarian Tumor Tissue Analysis consortium study
AU - Rambau, Peter F
AU - Vierkant, Robert A
AU - Intermaggio, Maria P
AU - Kelemen, Linda E
AU - Goodman, Marc T
AU - Herpel, Esther
AU - Pharoah, Paul D
AU - Kommoss, Stefan
AU - Jimenez-Linan, Mercedes
AU - Karlan, Beth Y
AU - Gentry-Maharaj, Aleksandra
AU - Menon, Usha
AU - Polo, Susanna Hernando
AU - Candido Dos Reis, Francisco J
AU - Doherty, Jennifer Anne
AU - Gayther, Simon A
AU - Sharma, Raghwa
AU - Larson, Melissa C
AU - Harnett, Paul R
AU - Hatfield, Emma
AU - de Andrade, Jurandyr M
AU - Nelson, Gregg S
AU - Steed, Helen
AU - Schildkraut, Joellen M
AU - Carney, Micheal E
AU - Høgdall, Estrid
AU - Whittemore, Alice S
AU - Widschwendter, Martin
AU - Kennedy, Catherine J
AU - Wang, Frances
AU - Wang, Qin
AU - Wang, Chen
AU - Armasu, Sebastian M
AU - Daley, Frances
AU - Coulson, Penny
AU - Jones, Micheal E
AU - Anglesio, Micheal S
AU - Chow, Christine
AU - de Fazio, Anna
AU - García-Closas, Montserrat
AU - Brucker, Sara Y
AU - Cybulski, Cezary
AU - Harris, Holly R
AU - Hartkopf, Andreas D
AU - Huzarski, Tomasz
AU - Jensen, Allan
AU - Lubiński, Jan
AU - Oszurek, Oleg
AU - Benitez, Javier
AU - Mina, Fady
AU - Staebler, Annette
AU - Taran, Florin Andrei
AU - Pasternak, Jana
AU - Talhouk, Aline
AU - Rossing, Mary Anne
AU - Hendley, Joy
AU - Edwards, Robert P
AU - Fereday, Sian
AU - Modugno, Francesmary
AU - Ness, Roberta B
AU - Sieh, Weiva
AU - El-Bahrawy, Mona A
AU - Winham, Stacey J
AU - Lester, Jenny
AU - Kjaer, Susanne K
AU - Gronwald, Jacek
AU - Sinn, Peter
AU - Fasching, Peter A
AU - Chang-Claude, Jenny
AU - Moysich, Kirsten B
AU - Bowtell, David D
AU - Hernandez, Brenda Y
AU - Luk, Hugh
AU - Behrens, Sabine
AU - Shah, Mitul
AU - Ghatage, Prafull
AU - Alsop, Jennifer
AU - Alsop, Kathryn
AU - García-Donas, Jesús
AU - Thompson, Pamela J
AU - Swerdlow, Anthony J
AU - Karpinskyj, Chloe
AU - Cazorla-Jiménez, Alicia
AU - García, María J
AU - Deen, Susha
AU - Wilkens, Lynne R
AU - Palacios, José
AU - Berchuck, Andrew
AU - Koziak, Jennifer M
AU - Brenton, James D
AU - Cook, Linda S
AU - Goode, Ellen L
AU - Huntsman, David G
AU - Ramus, Susan J
AU - Köbel, Martin
AU - AOCS study group
N1 - © 2018 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.
PY - 2018/10
Y1 - 2018/10
N2 - We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.
AB - We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.
KW - Journal Article
U2 - 10.1002/cjp2.109
DO - 10.1002/cjp2.109
M3 - SCORING: Journal article
C2 - 30062862
VL - 4
SP - 250
EP - 261
JO - J PATHOL CLIN RES
JF - J PATHOL CLIN RES
SN - 2056-4538
IS - 4
ER -